Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group-Reference-Cited by-同舟云学术

Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group

Published:2018-01 Issue:1 Volume:19 Page:e20-e32
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Camidge D Ross,Lee Eudocia Q,Lin Nancy U,Margolin Kim,Ahluwalia Manmeet S,Bendszus Martin,Chang Susan M,Dancey Janet,de Vries Elisabeth G E,Harris Gordon J,Hodi F Stephen,Lassman Andrew B,Macdonald David R,Peereboom David M,Schiff David,Soffietti Ricardo,van den Bent Martin J,Wefel Jeffrey S,Wen Patrick Y

Publisher

Elsevier BV

Subject

Oncology

Reference55 articles.

1. Updates in the management of brain metastases;Arvold;Neuro Oncol,2016

2. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial;Margolin;Lancet Oncol,2012

3. A brief report of the status of central nervous system metastasis enrollment criteria for advanced non-small cell lung cancer clinical trials: a review of the ClinicalTrials.gov trial registry;McCoach;J Thorac Oncol,2016

4. Response assessment criteria for brain metastases: proposal from the RANO group;Lin;Lancet Oncol,2015

5. Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group;Lin;Lancet Oncol,2013

Cited by 88 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial;ESMO Open;2024-09

2. Imaging Recommendations for Diagnosis, Staging, and Management of Central Nervous System Neoplasms in Adults: CNS Metastases;Cancers;2024-07-26

3. Preclinical evidence for the use of anti‐Trop‐2 antibody‐drug conjugate Sacituzumab govitecan in cerebral metastasized castration‐resistant prostate cancer;Cancer Medicine;2024-06

4. Antibody–drug conjugates are active in patients with HER2-positive breast cancer brain metastases: where do we go from here?;ESMO Open;2024-05

5. Updated Response Assessment in Neuro-Oncology (RANO) for Gliomas;Current Neurology and Neuroscience Reports;2024-01-03